Literature DB >> 9203652

Full or partial seroreversion in patients infected by hepatitis C virus.

J J Lefrère1, S Guiramand, F Lefrère, M Mariotti, P Aumont, J Lerable, J C Petit, R Girot, L Morand-Joubert.   

Abstract

Cases of partial seroreversion have been reported in hemodialyzed or immunodepressed patients, but spontaneous clearance of viremia associated with a disappearance of specific antibodies or clearance while receiving therapy has not been precisely documented in immunocompetent hepatitis C virus (HCV)-infected persons. A longitudinal study of markers of HCV infection in a cohort of 178 multitransfused patients followed over an 8-year period was done to establish well-documented cases of partial or full seroreversion. Thirty (16.8%) of 178 patients were HCV-infected; among them, 5 had partial or full seroreversion. Seroreversion to an anti-HCV-negative state is characterized by a quantitative decrease in antibody. A seroreversion may be observed in three circumstances: spontaneously, induced by therapy, and in conjunction with human immunodeficiency virus infection. Long-term follow-up of seroreverters will establish whether they have definitively eradicated HCV from their systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203652     DOI: 10.1093/infdis/175.2.316

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Fluctuating antibody response in a cohort of hepatitis C patients.

Authors:  Said H S Al Dhahry; Shahina Daar; Jameel C Nograles; Situsekara M W W B Rajapakse; Fadhila S S Al Toqi; Geraldine Z Kaminski
Journal:  J Sci Res Med Sci       Date:  2002-04

2.  Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.

Authors:  Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

3.  Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells.

Authors:  J Xiang; S Wünschmann; W Schmidt; J Shao; J T Stapleton
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population.

Authors:  L A Kondili; P Chionne; A Costantino; U Villano; C Lo Noce; F Pannozzo; A Mele; S Giampaoli; M Rapicetta
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

5.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05

6.  Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.

Authors:  Kimberly Page-Shafer; Brandee L Pappalardo; Leslie H Tobler; Bruce H Phelps; Brian R Edlin; Andrew R Moss; Teresa L Wright; David J Wright; Thomas R O'Brien; Sally Caglioti; Michael P Busch
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

7.  longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients.

Authors:  P Randhawa; D Bohl; D Brennan; K Ruppert; B Ramaswami; G Storch; J March; R Shapiro; R Viscidi
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

8.  Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy.

Authors:  Kaname Miyashita; Yui Hongo; Akihiko Nakashima; Seiya Kato; Hironori Kusano; Shusuke Morizono; Nobuhiko Higashi
Journal:  Intern Med       Date:  2020-11-16       Impact factor: 1.271

9.  Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles.

Authors:  S E Bassett; K M Brasky; R E Lanford
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

10.  Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load.

Authors:  Marion Cornelissen; Suzanne Jurriaans; Jan M Prins; Margreet Bakker; Antoinette C van der Kuyl
Journal:  AIDS Res Ther       Date:  2006-02-16       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.